Status:
RECRUITING
4FMFES-PET Imaging of ER+ Advanced Breast Cancers
Lead Sponsor:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Collaborating Sponsors:
Canadian Cancer Society (CCS)
Université de Sherbrooke
Conditions:
ER+ Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Estrogen Receptor (ER) is a crucial prognostic factor and treatment target in breast cancer patients. Knowledge of its status greatly influences the choice of the optimal course of treatment. Patholog...
Eligibility Criteria
Inclusion
- Advanced breast cancer patients, i.e. stage 3 or 4 diseases.
- Aged 18 or older at the time of breast cancer diagnosis.
- Histopathologic review confirming diagnosis of ER positive breast cancer.
- Male patients, although rare, can participate.
- Patient must have given informed consent.
- ECOG performance status 0-3.
- ER must be positive in at least 10% of tumor cells in either the core biopsy or a therapeutic surgical resection.
- Any HER2-neu status.
- Patient eligible for and willing to receive systemic treatment.
Exclusion
- Patients who are pregnant or nursing.
- Patients unable to tolerate PET/CT for 30 minutes.
- Patients taking anti-ER hormone therapy that can pharmacologically blockade estrogen receptors (ex: Tamoxifen, Fulvestrant). Patients can undergo 4FMFES-PET if anti-ER therapy was interrupted at least 8 weeks prior imaging. Aromatase inhibitors and LHRH analogs are not expected to interfere with 4FMFES uptake and are thus permitted to be taken prior and during this study.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04824014
Start Date
November 1 2020
End Date
December 31 2025
Last Update
February 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Université deSherbrooke
Sherbrooke, Quebec, Canada, J1H5N4